RU2008128424A - Фармацевтическая комбинация, включающая нуклеотидный и нуклеозидный ингибиторы обратной транскриптазы (такие как тенофовир и ламивудин) в различных частях дозы - Google Patents
Фармацевтическая комбинация, включающая нуклеотидный и нуклеозидный ингибиторы обратной транскриптазы (такие как тенофовир и ламивудин) в различных частях дозы Download PDFInfo
- Publication number
- RU2008128424A RU2008128424A RU2008128424/15A RU2008128424A RU2008128424A RU 2008128424 A RU2008128424 A RU 2008128424A RU 2008128424/15 A RU2008128424/15 A RU 2008128424/15A RU 2008128424 A RU2008128424 A RU 2008128424A RU 2008128424 A RU2008128424 A RU 2008128424A
- Authority
- RU
- Russia
- Prior art keywords
- reverse transcriptase
- transcriptase inhibitor
- pharmaceutical preparation
- preparation according
- tablet
- Prior art date
Links
- 102100034343 Integrase Human genes 0.000 title 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 title 1
- 239000002777 nucleoside Substances 0.000 title 1
- 150000003833 nucleoside derivatives Chemical class 0.000 title 1
- 229960004556 tenofovir Drugs 0.000 title 1
- SGOIRFVFHAKUTI-ZCFIWIBFSA-N tenofovir (anhydrous) Chemical compound N1=CN=C2N(C[C@@H](C)OCP(O)(O)=O)C=NC2=C1N SGOIRFVFHAKUTI-ZCFIWIBFSA-N 0.000 title 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims abstract 48
- 229940123527 Nucleotide reverse transcriptase inhibitor Drugs 0.000 claims abstract 27
- 229940122313 Nucleoside reverse transcriptase inhibitor Drugs 0.000 claims abstract 23
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 claims abstract 23
- 239000002552 dosage form Substances 0.000 claims abstract 20
- 238000004519 manufacturing process Methods 0.000 claims abstract 3
- 238000002360 preparation method Methods 0.000 claims abstract 3
- 239000011248 coating agent Substances 0.000 claims abstract 2
- 238000000576 coating method Methods 0.000 claims abstract 2
- 239000003826 tablet Substances 0.000 claims 27
- 239000010410 layer Substances 0.000 claims 19
- 229940127557 pharmaceutical product Drugs 0.000 claims 11
- 229940042402 non-nucleoside reverse transcriptase inhibitor Drugs 0.000 claims 9
- 239000002726 nonnucleoside reverse transcriptase inhibitor Substances 0.000 claims 9
- 229960001627 lamivudine Drugs 0.000 claims 7
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 claims 7
- 239000011230 binding agent Substances 0.000 claims 6
- 239000003085 diluting agent Substances 0.000 claims 6
- 239000000314 lubricant Substances 0.000 claims 6
- VCMJCVGFSROFHV-WZGZYPNHSA-N tenofovir disoproxil fumarate Chemical group OC(=O)\C=C\C(O)=O.N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N VCMJCVGFSROFHV-WZGZYPNHSA-N 0.000 claims 5
- XPOQHMRABVBWPR-UHFFFAOYSA-N Efavirenz Natural products O1C(=O)NC2=CC=C(Cl)C=C2C1(C(F)(F)F)C#CC1CC1 XPOQHMRABVBWPR-UHFFFAOYSA-N 0.000 claims 4
- 229960003804 efavirenz Drugs 0.000 claims 4
- XPOQHMRABVBWPR-ZDUSSCGKSA-N efavirenz Chemical compound C([C@]1(C2=CC(Cl)=CC=C2NC(=O)O1)C(F)(F)F)#CC1CC1 XPOQHMRABVBWPR-ZDUSSCGKSA-N 0.000 claims 4
- 239000000843 powder Substances 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 3
- 208000031886 HIV Infections Diseases 0.000 claims 2
- 208000037357 HIV infectious disease Diseases 0.000 claims 2
- 239000013543 active substance Substances 0.000 claims 2
- 239000011247 coating layer Substances 0.000 claims 2
- WHBIGIKBNXZKFE-UHFFFAOYSA-N delavirdine Chemical compound CC(C)NC1=CC=CN=C1N1CCN(C(=O)C=2NC3=CC=C(NS(C)(=O)=O)C=C3C=2)CC1 WHBIGIKBNXZKFE-UHFFFAOYSA-N 0.000 claims 2
- 239000007884 disintegrant Substances 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- -1 emitricitabine Chemical compound 0.000 claims 2
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 2
- NQDJXKOVJZTUJA-UHFFFAOYSA-N nevirapine Chemical compound C12=NC=CC=C2C(=O)NC=2C(C)=CC=NC=2N1C1CC1 NQDJXKOVJZTUJA-UHFFFAOYSA-N 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- XNKLLVCARDGLGL-JGVFFNPUSA-N Stavudine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1C=C[C@@H](CO)O1 XNKLLVCARDGLGL-JGVFFNPUSA-N 0.000 claims 1
- 229960004748 abacavir Drugs 0.000 claims 1
- MCGSCOLBFJQGHM-SCZZXKLOSA-N abacavir Chemical compound C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1 MCGSCOLBFJQGHM-SCZZXKLOSA-N 0.000 claims 1
- 229960001997 adefovir Drugs 0.000 claims 1
- WOZSCQDILHKSGG-UHFFFAOYSA-N adefovir depivoxil Chemical compound N1=CN=C2N(CCOCP(=O)(OCOC(=O)C(C)(C)C)OCOC(=O)C(C)(C)C)C=NC2=C1N WOZSCQDILHKSGG-UHFFFAOYSA-N 0.000 claims 1
- 239000011324 bead Substances 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229960005319 delavirdine Drugs 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000000945 filler Substances 0.000 claims 1
- 239000008187 granular material Substances 0.000 claims 1
- 229960000689 nevirapine Drugs 0.000 claims 1
- 229940042126 oral powder Drugs 0.000 claims 1
- 229940100688 oral solution Drugs 0.000 claims 1
- 229940100692 oral suspension Drugs 0.000 claims 1
- 239000000902 placebo Substances 0.000 claims 1
- 229940068196 placebo Drugs 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 229960001203 stavudine Drugs 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 229960002555 zidovudine Drugs 0.000 claims 1
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN1566/MUM/2005 | 2005-12-14 | ||
| IN1566MU2005 | 2005-12-14 | ||
| IN1878MU2006 | 2006-11-13 | ||
| IN1878/MUM/2006 | 2006-11-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2008128424A true RU2008128424A (ru) | 2010-01-20 |
Family
ID=38163276
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2008128424/15A RU2008128424A (ru) | 2005-12-14 | 2006-12-14 | Фармацевтическая комбинация, включающая нуклеотидный и нуклеозидный ингибиторы обратной транскриптазы (такие как тенофовир и ламивудин) в различных частях дозы |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20080317852A1 (https=) |
| EP (1) | EP2051703B1 (https=) |
| JP (1) | JP5231242B2 (https=) |
| KR (1) | KR20080091767A (https=) |
| AP (1) | AP2008004533A0 (https=) |
| AT (1) | ATE474560T1 (https=) |
| AU (1) | AU2006325404B2 (https=) |
| BR (1) | BRPI0620705A2 (https=) |
| CA (1) | CA2633603C (https=) |
| DE (1) | DE602006015721D1 (https=) |
| MA (1) | MA30161B1 (https=) |
| NZ (1) | NZ569349A (https=) |
| RU (1) | RU2008128424A (https=) |
| SI (1) | SI2051703T1 (https=) |
| WO (1) | WO2007068934A2 (https=) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2660438C1 (ru) * | 2014-07-18 | 2018-07-06 | Джей ДаблЮ ФАРМАСЬЮТИКАЛ КОРПОРЭЙШН | Новая соль тенофовира дизопроксила |
| RU2662160C1 (ru) * | 2017-07-03 | 2018-07-24 | Александрович Иващенко Андрей | Комбинированный лекарственный препарат для терапии вирусных инфекций |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA05007016A (es) | 2003-01-14 | 2005-09-12 | Gilead Sciences Inc | Composiciones y metodos para terapia antiviral de combinacion. |
| TWI471145B (zh) | 2005-06-13 | 2015-02-01 | Bristol Myers Squibb & Gilead Sciences Llc | 單一式藥學劑量型 |
| TWI375560B (en) | 2005-06-13 | 2012-11-01 | Gilead Sciences Inc | Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same |
| WO2009037449A1 (en) * | 2007-09-18 | 2009-03-26 | Cipla Limited | Solid pharmaceutical compositions comprising one or more herpes virus inhibitors and one or more reverse transcriptase inhibitors |
| GT200800303A (es) * | 2007-12-24 | 2009-09-18 | Combinacion anti-retroviral | |
| WO2009106954A1 (en) * | 2008-02-27 | 2009-09-03 | Aurobindo Pharma Limited | Stable dosage forms of lamivudine and tenofovir |
| WO2009106960A2 (en) * | 2008-02-27 | 2009-09-03 | Aurobindo Pharma Limited | Stable compositions of lamivudine, tenofovir and efavirenz |
| HRP20151357T1 (hr) | 2008-05-02 | 2016-01-29 | Gilead Sciences, Inc. | Upotreba äśestica äśvrstog nosaäśa kako bi se poboljšala procesabilnost farmaceutskog agensa |
| DK2393485T3 (en) * | 2009-02-06 | 2015-10-26 | Gilead Sciences Inc | Bilayer COVERING ELVITEGRAVIR, COBICISTAT, emtricitabine and tenofovir |
| WO2010125572A1 (en) * | 2009-04-29 | 2010-11-04 | Hetero Research Foundation | Compressed tablets and capsules containing efavirenz |
| US8481554B2 (en) | 2009-05-27 | 2013-07-09 | Hetero Research Foundation | Solid oral dosage forms of lamivudine |
| EP2389929A1 (en) * | 2010-05-30 | 2011-11-30 | Abdi Ibrahim Ilac Sanayi ve Ticaret Anonim Sirketi | Pharmaceutical formulations of tenofovir |
| CN114010776A (zh) | 2010-06-09 | 2022-02-08 | 疫苗技术股份有限公司 | 用于增强抗逆转录病毒治疗的hiv感染者的治疗性免疫 |
| SG10201509521WA (en) | 2010-11-19 | 2015-12-30 | Gilead Sciences Inc | Therapeutic compositions comprising rilpivirine hcl and tenofovir disoproxil fumarate |
| CA2835272A1 (en) * | 2011-05-30 | 2012-12-06 | Cipla Limited | Pharmaceutical antiretroviral composition |
| CN103211826A (zh) * | 2013-05-14 | 2013-07-24 | 福建广生堂药业股份有限公司 | 一种抗病毒药物组合物及其制备方法和用途 |
| EP2832351A1 (en) * | 2013-07-29 | 2015-02-04 | Sanovel Ilac Sanayi ve Ticaret A.S. | Multilayer Tablet Formulations Comprising Tenofovir and Entecavir |
| CN104473896B (zh) * | 2014-12-01 | 2017-04-19 | 东莞市金美济药业有限公司 | 一种快速崩解的拉米夫定片及其制备工艺 |
| WO2017095761A1 (en) | 2015-12-02 | 2017-06-08 | Merck Sharp & Dohme Corp. | Pharmaceutical compositions containing doravirine, tenofovir disoproxil fumarate and lamivudine |
| TR201617448A2 (tr) | 2016-11-29 | 2018-06-21 | Arven Ilac Sanayi Ve Ticaret Anonim Sirketi | Tenofovi̇r ve emtri̇si̇tabi̇n i̇çeren kati oral farmasöti̇k bi̇leşi̇mler |
| CN106822155B (zh) * | 2016-12-29 | 2019-10-11 | 东北制药集团股份有限公司 | 依非韦伦、拉米夫定及富马酸替诺福韦酯三联复方片中片及其制备方法 |
| RU2644156C1 (ru) | 2017-02-28 | 2018-02-08 | Александр Васильевич Иващенко | Пролекарство ингибитора NS5B HCV полимеразы, способ его получения и применения |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE556141A (https=) * | 1956-03-27 | |||
| CS263951B1 (en) * | 1985-04-25 | 1989-05-12 | Antonin Holy | 9-(phosponylmethoxyalkyl)adenines and method of their preparation |
| US5047407A (en) * | 1989-02-08 | 1991-09-10 | Iaf Biochem International, Inc. | 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties |
| US5366972A (en) * | 1989-04-20 | 1994-11-22 | Boehringer Ingelheim Pharmaceuticals, Inc. | 5,11-dihydro-6H-dipyrido(3,2-B:2',3'-E)(1,4)diazepines and their use in the prevention or treatment of HIV infection |
| US6057305A (en) * | 1992-08-05 | 2000-05-02 | Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic | Antiretroviral enantiomeric nucleotide analogs |
| US5665720A (en) * | 1992-08-07 | 1997-09-09 | Merck & Co., Inc. | Benzoxazinones as inhibitors of HIV reverse transcriptase |
| IT1264696B1 (it) * | 1993-07-09 | 1996-10-04 | Applied Pharma Res | Forme farmaceutiche destinate alla somministrazione orale in grado di rilasciare sostanze attive a velocita' controllata e differenziata |
| US5922695A (en) * | 1996-07-26 | 1999-07-13 | Gilead Sciences, Inc. | Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability |
| US5733788A (en) * | 1996-07-26 | 1998-03-31 | Gilead Sciences, Inc. | PMPA preparation |
| US5935946A (en) * | 1997-07-25 | 1999-08-10 | Gilead Sciences, Inc. | Nucleotide analog composition and synthesis method |
| UA72207C2 (uk) * | 1998-04-07 | 2005-02-15 | Брістол- Майєрс Сквібб Фарма Компані | Фармацевтична композиція ефавіренцу з добавкою дезінтегруючих агентів у вигляді швидкорозчинних капсул або таблеток та спосіб її виготовлення |
| GB9820420D0 (en) * | 1998-09-18 | 1998-11-11 | Glaxo Group Ltd | Antiviral combinations |
| ZA200110501B (en) * | 2001-05-11 | 2002-04-03 | Cipla Medpro Pty Ltd | Pharmaceutical composition. |
| ZA200110499B (en) * | 2001-05-11 | 2002-04-03 | Cipla Medpro Pty Ltd | Pharmaceutical composition. |
| MY169670A (en) * | 2003-09-03 | 2019-05-08 | Tibotec Pharm Ltd | Combinations of a pyrimidine containing nnrti with rt inhibitors |
| AU2002311622A1 (en) * | 2002-04-23 | 2003-11-10 | Lupin Limited | Long acting compositions comprising zidovudine and lamivudine |
| AU2003231765B9 (en) * | 2002-04-26 | 2010-01-28 | Gilead Sciences, Inc. | Cellular accumulation of phosphonate analogs of HIV protease inhibitor compounds and the compounds as such |
| US20050287177A1 (en) * | 2002-11-08 | 2005-12-29 | Glaxo Group Unlimited And Smithkline Beecham Corp. | Pharmaceutical compositions |
| MXPA05007016A (es) * | 2003-01-14 | 2005-09-12 | Gilead Sciences Inc | Composiciones y metodos para terapia antiviral de combinacion. |
| US20050048112A1 (en) * | 2003-08-28 | 2005-03-03 | Jorg Breitenbach | Solid pharmaceutical dosage form |
| TWI471145B (zh) * | 2005-06-13 | 2015-02-01 | Bristol Myers Squibb & Gilead Sciences Llc | 單一式藥學劑量型 |
| WO2007013047A2 (en) * | 2005-07-29 | 2007-02-01 | Ranbaxy Laboratories Limited | Water-dispersible anti-retroviral pharmaceutical compositions |
-
2006
- 2006-12-14 AT AT06820527T patent/ATE474560T1/de not_active IP Right Cessation
- 2006-12-14 JP JP2008545090A patent/JP5231242B2/ja active Active
- 2006-12-14 EP EP06820527A patent/EP2051703B1/en not_active Not-in-force
- 2006-12-14 RU RU2008128424/15A patent/RU2008128424A/ru not_active Application Discontinuation
- 2006-12-14 AP AP2008004533A patent/AP2008004533A0/xx unknown
- 2006-12-14 KR KR1020087016727A patent/KR20080091767A/ko not_active Ceased
- 2006-12-14 CA CA2633603A patent/CA2633603C/en not_active Expired - Fee Related
- 2006-12-14 US US12/097,387 patent/US20080317852A1/en not_active Abandoned
- 2006-12-14 DE DE602006015721T patent/DE602006015721D1/de active Active
- 2006-12-14 AU AU2006325404A patent/AU2006325404B2/en not_active Ceased
- 2006-12-14 BR BRPI0620705-7A patent/BRPI0620705A2/pt not_active IP Right Cessation
- 2006-12-14 SI SI200630809T patent/SI2051703T1/sl unknown
- 2006-12-14 NZ NZ569349A patent/NZ569349A/en unknown
- 2006-12-14 WO PCT/GB2006/004687 patent/WO2007068934A2/en not_active Ceased
-
2008
- 2008-07-11 MA MA31114A patent/MA30161B1/fr unknown
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2660438C1 (ru) * | 2014-07-18 | 2018-07-06 | Джей ДаблЮ ФАРМАСЬЮТИКАЛ КОРПОРЭЙШН | Новая соль тенофовира дизопроксила |
| RU2662160C1 (ru) * | 2017-07-03 | 2018-07-24 | Александрович Иващенко Андрей | Комбинированный лекарственный препарат для терапии вирусных инфекций |
| RU2662160C9 (ru) * | 2017-07-03 | 2018-10-22 | Александрович Иващенко Андрей | Комбинированный лекарственный препарат для терапии вирусных инфекций |
Also Published As
| Publication number | Publication date |
|---|---|
| DE602006015721D1 (de) | 2010-09-02 |
| JP2009519311A (ja) | 2009-05-14 |
| EP2051703B1 (en) | 2010-07-21 |
| ATE474560T1 (de) | 2010-08-15 |
| SI2051703T1 (sl) | 2011-01-31 |
| CA2633603C (en) | 2016-09-13 |
| CA2633603A1 (en) | 2007-06-21 |
| JP5231242B2 (ja) | 2013-07-10 |
| WO2007068934A3 (en) | 2008-02-21 |
| WO2007068934A2 (en) | 2007-06-21 |
| AU2006325404A1 (en) | 2007-06-21 |
| KR20080091767A (ko) | 2008-10-14 |
| BRPI0620705A2 (pt) | 2011-11-22 |
| NZ569349A (en) | 2012-01-12 |
| EP2051703A2 (en) | 2009-04-29 |
| AP2008004533A0 (en) | 2008-08-31 |
| AU2006325404B2 (en) | 2012-03-01 |
| US20080317852A1 (en) | 2008-12-25 |
| MA30161B1 (fr) | 2009-01-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2008128424A (ru) | Фармацевтическая комбинация, включающая нуклеотидный и нуклеозидный ингибиторы обратной транскриптазы (такие как тенофовир и ламивудин) в различных частях дозы | |
| Lemaitre et al. | Management of drug-drug interactions with nirmatrelvir/ritonavir in patients treated for Covid-19: guidelines from the French Society of Pharmacology and Therapeutics (SFPT) | |
| JP2009519311A5 (https=) | ||
| RU2616516C2 (ru) | Фармацевтическая композиция, содержащая олмесартана медоксомил и розувастатин или его соль | |
| WO2014184553A1 (en) | Pharmaceutical antiretroviral compositions | |
| EP2911674A1 (en) | Pharmaceutical antiretroviral composition | |
| EP2822560A1 (en) | Pharmaceutical antiretroviral combinations comprising lamivudine, festinavir and nevirapine | |
| KR20110007602A (ko) | 심장혈관계 질병 예방용 캡슐 | |
| JP2021535107A5 (https=) | ||
| Nelson et al. | Emtricitabine (FTC) for the treatment of HIV infection | |
| WO2009106954A1 (en) | Stable dosage forms of lamivudine and tenofovir | |
| US20140193491A1 (en) | Pharmaceutical antiretroviral composition | |
| Agarwal et al. | A review on tablet in tablet for cancer and use of artificial intelligence (AI) | |
| KR20250016304A (ko) | 혈액 응고 치료 및 저항용 약제학적 조성물 및 이의 용도 | |
| US20260102370A1 (en) | Methods of treating obesity in responder and non-responder populations | |
| WO2009037449A1 (en) | Solid pharmaceutical compositions comprising one or more herpes virus inhibitors and one or more reverse transcriptase inhibitors | |
| EP2830605B1 (en) | A combination medicament comprising phenylephrine and paracetamol | |
| EP3496719B1 (en) | A multi-class anti-retroviral composition | |
| WO2018028841A1 (en) | Solid pharmaceutical composition of abacavir, lamivudine, and efavirenz | |
| Gaur et al. | Prospectives and potentials of bilayer technology: a novel approach | |
| WO2017029226A1 (en) | Solid pharmaceutical composition of abacavir, lamivudine, and efavirenz | |
| Merry et al. | Antiretroviral Drugs | |
| Struble et al. | Drug interactions with antiretrovirals for HIV infection | |
| KR20150105496A (ko) | 다폭세틴 및 염산클로미프라민으로부터 선택되는 조루치료제 및 pde5 억제제가 분리된 형태로 존재하는 경구투여 약제학적 제형 | |
| CN101277683A (zh) | 普那卡生的延迟制剂 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20100622 |